CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

The nitroxyl (HNO) prodrug, CXL-1020, induces vasorelaxation and improves cardiac function in canine models and patients with systolic heart failure (HF). HNO's unique mechanism of action may be applicable to a broader subset of cardiac patients. This study investigated the load-independent saf...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in physiology Ročník 8; s. 894
Hlavní autoři: Roof, Steve R., Ueyama, Yukie, Mazhari, Reza, Hamlin, Robert L., Hartman, J. Craig, Ziolo, Mark T., Reardon, John E., del Rio, Carlos L.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 10.11.2017
Témata:
cardiac diastolic dysfunction
cardiovascular therapeutic
CXL-1020
nitroxyl
Physiology
cardiac diastolic dysfunction
cardiovascular therapeutic
nitroxyl
CXL-1020
ISSN:1664-042X, 1664-042X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The nitroxyl (HNO) prodrug, CXL-1020, induces vasorelaxation and improves cardiac function in canine models and patients with systolic heart failure (HF). HNO's unique mechanism of action may be applicable to a broader subset of cardiac patients. This study investigated the load-independent safety and efficacy of CXL-1020 in two rodent (rat) models of diastolic heart failure and explored potential drug interactions with common HF background therapies. left-ventricular hemodynamics/pressure-volume relationships assessed before/during a 30 min IV infusion of CXL-1020 demonstrated acute load-independent positive inotropic, lusitropic, and vasodilatory effects in normal rats. In rats with only diastolic dysfunction due to bilateral renal wrapping (RW) or pronounced diastolic and mild systolic dysfunction due to 4 weeks of chronic isoproterenol exposure (ISO), CXL-1020 attenuated the elevated LV filling pressures, improved the end diastolic pressure volume relationship, and accelerated relaxation. CXL-1020 facilitated Ca re-uptake and enhanced myocyte relaxation in isolated cardiomyocytes from ISO rats. Compared to milrinone, CXL-1020 more effectively improved Ca reuptake in ISO rats without concomitant chronotropy, and did not enhance Ca entry via L-type Ca channels nor increase myocardial arrhythmias/ectopic activity. Acute-therapy with CXL-1020 improved ventricular relaxation and Ca cycling, in the setting of chronic induced diastolic dysfunction. CXL-1020's lusitropic effects were greater than those seen with the cAMP-dependent agent milrinone, and unlike milrinone it did not produce chronotropy or increased ectopy. HNO is a promising new potential therapy for both systolic and diastolic heart failure.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: John James Mackrill, University College Cork, Ireland; Bin-Nan Wu, Kaohsiung Medical University, Taiwan
This article was submitted to Clinical and Translational Physiology, a section of the journal Frontiers in Physiology
Edited by: Gaetano Santulli, Columbia University, United States
ISSN:1664-042X
1664-042X
DOI:10.3389/fphys.2017.00894